Avadel Pharmaceuticals PLC Sponsored ADR Stock News

DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hyp...

– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data reflecting the therapeutic results of LUMRYZ treatment in people with narcolepsy across clinical as well as real-world settings will ...

DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 10:30 a.m. ET. A live webcast of the fireside chat, as well as an archived...

Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter the idiopathic hypersomnia market after a favorable court ruling. Analysts remain bullish, reiterating Buy ratings and projecting significant revenue and profit growth through FY2026 as LUMRYZ adop...

DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, an...

DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m.

DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to nine (9) new employees to purchase 51,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as a...

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Mark Goodman - Leerink David Huang - Deutsche Bank Myriam Belghiti - LSC Ami Fadia - Needham Chase Knickerbocker - Craig Hallum Operator Gre...